


We claim:

1. A compound having the structure of Formula I, or a pharmaceutically acceptable salt thereof:



wherein:

X is a 5- to 14-membered heteroaryl containing 1-3 heteroatoms;

R¹ is hydrogen, halogen, C₁-C₆alkyl, C₃-C₆cycloalkyl, or C₂-C₆alkenyl; wherein said alkyl, cycloalkyl or alkenyl is optionally substituted with one to three substituents each independently selected from the group consisting of fluoro, hydroxyl and C₁-C₆alkoxy;

A is a C₃-C₆cycloalkyl or a 4- to 10-membered heterocycloalkyl; wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of halogen and C₁-C₆alkyl;

R^{2a} and R^{2b} for each occurrence is independently hydrogen, fluoro, cyano, -CF₃, C₁-C₆alkyl, C₂-C₆alkenyl, C₃-C₆cycloalkyl, C₄-C₈bicycloalkyl, C₂-C₆alkynyl or phenyl; wherein said alkyl, alkenyl, cycloalkyl, bicycloalkyl, alkynyl or phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano, C₁-C₃alkyl and fluoro; or R^{2a} and R^{2b} together with the carbon to which they are bonded form a 3- to 5-membered cycloalkyl optionally substituted with one to three of R⁸;

R^3 is hydrogen, halogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, $-(C(R^{10})_2)_t-(C_3$ - C_6 cycloalkyl), $-(C(R^{10})_2)_t$ -(4- to 10-membered heterocycloalkyl), $-(C(R^{10})_2)_t-(C_6$ - C_{10} aryl), $-(C(R^{10})_2)_t$ -(5- to 10-membered heteroaryl) or $-(C(R^{10})_2)_t-OR^{12}$; wherein said alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one to five of R^{11} ;

5 R^{4a} and R^{4b} are each independently hydrogen, $-CF_3$, or C_1 - C_6 alkyl, wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of $-CF_3$, cyano and fluoro; or R^{4a} and R^{4b} together with the carbon to which they are bonded form a 3- to 5-membered cycloalkyl, wherein said cycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of $-CF_3$, cyano, fluoro and C_1 - C_6 alkyl;

10 R^{5a} and R^{5b} for each occurrence are each independently hydrogen, $-CF_3$, or C_1 - C_6 alkyl, wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of $-CF_3$, cyano and fluoro; or R^{5a} and R^{5b} together with the carbon to which they are bonded form a 3- to 5-membered cycloalkyl, wherein said cycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of $-CF_3$, cyano, fluoro and C_1 - C_6 alkyl;

R^6 , R^7 and R^8 are each independently hydrogen, $-CF_3$, cyano, halogen, C_1 - C_6 alkyl, or $-OR^9$; provided that R^6 and R^7 cannot both be $-OH$;

20 R^9 is hydrogen, C_1 - C_6 alkyl or $-CF_3$; wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano and fluoro;

each R^{10} is independently hydrogen, halogen, cyano, $-CF_3$, C_1 - C_6 alkyl, or $-SF_5$; wherein said alkyl is optionally substituted with one to three fluoro;

25 each R^{11} is independently hydrogen, halogen, $-CF_3$, $-SF_5$, $-Si(CH_3)_3$, $-OR^{12}$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-(C(R^{10})_2)_t-(C_3$ - C_6 cycloalkyl), $-(C(R^{10})_2)_t-(C_6$ - C_{10} aryl) or $-(C(R^{10})_2)_t$ -(5- to 10-membered heteroaryl) wherein said $-Si(CH_3)_3$, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl is optionally substituted with one to five substituents each independently selected from the group consisting of halogen and $-CF_3$;

30 each R^{12} is hydrogen, C_1 - C_6 alkyl, $-(C(R^{13})_2)_n-(C_3$ - C_6 cycloalkyl), $-(C(R^{13})_2)_n$ -(4- to 10-membered heterocycloalkyl), $-(C(R^{13})_2)_n-(C_6$ - C_{10} aryl), or $-(C(R^{13})_2)_n$ -(5- to 10-

membered heteroaryl); wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one to five of R¹⁴;

each R¹³ is independently hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, halogen, cyano, -CF₃, or -OCF₃;

5 R¹⁴ is independently hydrogen, -CF₃, cyano, halogen or C₁₋₆alkyl; wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of hydroxyl, -CF₃, cyano and fluoro; and

each t or n is an integer independently selected from 0, 1, 2 or 3;

each z is an integer independently selected from 1 or 2;

10 each y is an integer independently selected from 0, 1, 2, 3 or 4.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, oxazolyl or pyridyl; and R¹ is C₁-C₆alkyl.

3. The compound according to any one of claims 1 or 2, or a
15 pharmaceutically acceptable salt thereof, wherein X is imidazolyl; and R¹ is methyl.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein z is 1; and R^{4a} and R^{4b} are each independently hydrogen or methyl.

5. The compound according to any one of claims 1 to 4, or a
20 pharmaceutically acceptable salt thereof, wherein R^{5a}, R^{5b}, R⁶, and R⁷ are independently hydrogen.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein y is 0 or 1; and R^{2a} and R^{2b} are independently hydrogen or methyl.

25 7. The compound according to any of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A is cyclobutyl, cyclopentyl, or cyclohexyl.

8. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein A is dihydroisoxazolyl, tetrahydrofuranyl or tetrahydropyranyl.
30

9. The compound according to claim 8, or a pharmaceutically acceptable salt

thereof, wherein A is tetrahydrofuranyl.

10. The compound according to claim 8, or a pharmaceutically acceptable salt thereof,

wherein A is tetrahydropyranyl.


11. The compound according to any one of claims 6 to 10, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-(C_6-C_{10}aryl)$ or $-(C(R^{10})_2)_t-OR^{12}$; and t is 0 or 1.

12. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-(C_6-C_{10}aryl)$; t is 0; and said aryl is phenyl optionally substituted with one to three R^{11} , wherein R^{11} is selected from the group consisting of fluoro, chloro, $-CF_3$, $-SF_5$, $-OR^{12}$, C_1-C_3alkyl , and $C_3-C_6cycloalkyl$; wherein said alkyl or said cycloalkyl is optionally and independently substituted with one to three substituents selected from the group consisting of halogen and $-CF_3$.

13. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-(5- \text{ to } 10\text{-membered heteroaryl})$ and said heteroaryl is thiophenyl optionally substituted with one to three R^{11} , wherein R^{11} is selected from the group consisting of fluoro, chloro and, $-CF_3$.

14. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-OR^{12}$; t is 0; and R^{12} is selected from phenyl, naphthyl or dihydroindenyl; wherein said phenyl, naphthyl or dihydroindenyl is optionally and independently substituted with one to three R^{14} selected from the group consisting of fluoro, chloro, $-CF_3$, and C_1-C_3alkyl ; wherein said alkyl may be independently substituted with one to three substituents selected from the group consisting of halogen and $-CF_3$.

15. A compound of Formula Id, or a pharmaceutically acceptable salt thereof:



wherein:

R^2 is hydrogen or methyl; R^3 is $-(C(R^{10})_2)_t-(C_6-C_{10}\text{aryl})$ or $-(C(R^{10})_2)_t-(5\text{- to }10\text{-membered heteroaryl})$, wherein said aryl or heteroaryl is optionally substituted with one to three R^{11} independently selected from the group consisting of fluoro, chloro, $-\text{CF}_3$, $-\text{SF}_5$, $-\text{OCH}_3$, $-\text{OCF}_3$, and $-\text{OCHF}_2$; R^{10} is independently hydrogen, halogen, cyano, $-\text{CF}_3$, $\text{C}_1\text{-C}_6\text{alkyl}$, or $-\text{SF}_5$, wherein said alkyl is optionally substituted with one to three fluoro; and t is 0 or 1.

16. The compound according to claim 15, or a pharmaceutically acceptable salt thereof, wherein t is 0; and R^3 is phenyl optionally substituted with one to three R^{11} .

17. The compound according to claim 15, or a pharmaceutically acceptable salt thereof, wherein R^3 is thiophenyl optionally substituted with one to three R^{11} .

18. The compound according to claim 15, or a pharmaceutically acceptable salt thereof, wherein said compound is:

7-(4-methyl-1*H*-imidazol-1-yl)-2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[3,5-difluoro-4-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-(4-chloro-3,5-difluorophenyl)tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4,5-difluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-fluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

5 2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;


10 2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-3-fluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

19. Use of a compound as defined according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of neurodegeneration and psychiatric disorders, including Alzheimer's Disease or Niemann-Pick type C disease.

15 20. A pharmaceutical composition comprising a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

CLAIMS

1. A compound having the structure of Formula I, or a pharmaceutically acceptable salt thereof:



wherein:

X is a 5- to 14-membered heteroaryl containing 1-3 heteroatoms;

R¹ is hydrogen, halogen, C₁-C₆alkyl, C₃-C₆cycloalkyl, or C₂-C₆alkenyl; wherein said alkyl, cycloalkyl or alkenyl is optionally substituted with one to three substituents each independently selected from the group consisting of fluoro, hydroxy and C₁-C₆alkoxy;

A is a C₃-C₆cycloalkyl or a 4- to 10-membered heterocycloalkyl; wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of halogen and C₁-C₆alkyl;

R^{2a} and R^{2b} for each occurrence is independently hydrogen, fluoro, cyano, C₁-C₆alkyl, C₂-C₆alkenyl, C₃-C₆cycloalkyl, C₄-C₈bicycloalkyl, C₂-C₆alkynyl or phenyl; wherein said alkyl, alkenyl, cycloalkyl, bicycloalkyl, alkynyl or phenyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano, C₁-C₃alkyl and fluoro; or R^{2a} and R^{2b} together with the carbon to which they are bonded form a 3- to 5-membered cycloalkyl optionally substituted with one to three of R⁸;

R³ is hydrogen, halogen, C₁-C₆alkyl, C₂-C₆alkenyl, -(C(R¹⁰)₂)_t-(C₃-C₆cycloalkyl), -(C(R¹⁰)₂)_t-(4- to 10-membered heterocycloalkyl), -(C(R¹⁰)₂)_t-(C₆-C₁₀aryl), -(C(R¹⁰)₂)_t-(5- to 10-membered heteroaryl) or -(C(R¹⁰)₂)_t-OR¹²; wherein said alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one to five of R¹¹;

R^{4a} and R^{4b} are each independently hydrogen, or C₁-C₆alkyl, wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano and fluoro;

R^{5a} and R^{5b} for each occurrence are each independently hydrogen, or C₁-C₆alkyl, wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano and fluoro;

R⁶, R⁷ and R⁸ are each independently hydrogen, -CF₃, cyano, halogen, C₁-C₆alkyl, or -OR⁹; provided that R⁶ and R⁷ cannot both be -OH;

R⁹ is hydrogen, or C₁-C₆alkyl; wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano and fluoro;

each R¹⁰ is independently hydrogen, halogen, cyano, C₁-C₆alkyl, or -SF₅; wherein said alkyl is optionally substituted with one to three fluoro;

each R¹¹ is independently hydrogen, halogen, -SF₅, -Si(CH₃)₃, OR¹², C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, -(C(R¹⁰)₂)_t-(C₃-C₆cycloalkyl), -(C(R¹⁰)₂)_t-(C₆-C₁₀aryl) or -(C(R¹⁰)₂)_t-(5- to 10-membered heteroaryl) wherein said -Si(CH₃)₃, alkyl, alkenyl, or alkynyl, cycloalkyl, aryl or heteroaryl is optionally substituted with one to five substituents each independently selected from the group consisting of halogen and -CF₃;

each R¹² is hydrogen, C₁-C₆alkyl, -(C(R¹³)₂)_n-(C₃-C₆cycloalkyl), -(C(R¹³)₂)_n-(4- to 10-membered heterocycloalkyl), -(C(R¹³)₂)_n-(C₆-C₁₀aryl), or -(C(R¹³)₂)_n-(5- to 10-membered heteroaryl); wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one to five of R¹⁴;

each R¹³ is independently hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, halogen, cyano, -CF₃, or -OCF₃;

R¹⁴ is independently hydrogen, -CF₃, cyano, halogen or C₁-C₆alkyl; wherein said alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of hydroxy, cyano and fluoro; and

each t or n is an integer independently selected from 0, 1, 2 or 3;

each z is 1;

each y is an integer independently selected from 0, 1, 2, 3 or 4.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, oxazolyl or pyridyl; and R¹ is C₁-C₆alkyl.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X is imidazolyl; and R¹ is methyl.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R^{4a} and R^{4b} are each independently hydrogen or methyl.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R^{5a} , R^{5b} , R^6 , and R^7 are independently hydrogen.

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein y is 0 or 1; and R^{2a} and R^{2b} are independently hydrogen or methyl.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A is cyclobutyl, cyclopentyl, or cyclohexyl.

8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A is dihydroisoxazolyl, tetrahydrofuranyl or tetrahydropyranyl.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein A is tetrahydrofuranyl.

10. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-(C_6-C_{10}aryl)$ or $-(C(R^{10})_2)_t-OR^{12}$; and t is 0 or 1.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-(C_6-C_{10}aryl)$; t is 0; and said aryl is phenyl optionally substituted with one to three R^{11} , wherein R^{11} is selected from the group consisting of fluoro, chloro, $-SF_5$, OR^{12} , C_1-C_3alkyl , and $C_3-C_6cycloalkyl$; wherein said alkyl or said cycloalkyl is optionally and independently substituted with one to three substituents selected from the group consisting of halogen and $-CF_3$.


12. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-(5- \text{ to } 10\text{-membered heteroaryl})$; t is 0; and said heteroaryl is thiophenyl optionally substituted with one to three R^{11} , wherein R^{11} is selected from the group consisting of fluoro, chloro and, $-CF_3$.

13. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R^3 is $-(C(R^{10})_2)_t-OR^{12}$; t is 0; and R^{12} is selected from phenyl, naphthyl or dihydroindenyl; wherein said phenyl, naphthyl or dihydroindenyl is optionally and independently substituted with one to three R^{14} selected from the group consisting of fluoro, chloro, and C_1-C_3alkyl ; wherein said alkyl may be independently substituted with one to three halogen.

14. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein A is tetrahydropyranyl.

15. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

16. A compound of Formula Id, or a pharmaceutically acceptable salt thereof:



wherein:

R^2 is hydrogen or methyl; R^3 is $-(C(R^{10})_2)_t-(C_6-C_{10}\text{aryl})$ or $-(C(R^{10})_2)_t-(5\text{- to } 10\text{-membered heteroaryl})$, wherein said aryl or heteroaryl is optionally substituted with one to three R^{11} independently selected from the group consisting of fluoro, chloro, methyl, $-CF_3$, $-SF_5$, $-OCH_3$, $-OCF_3$, $-CF_2(CH_3)$ and $-OCHF_2$; R^{10} is independently hydrogen, halogen, cyano, C_1-C_6 alkyl, or $-SF_5$; wherein said alkyl is optionally substituted with one to three fluoro; and t is 0 or 1.

17. The compound according to claim 16, or a pharmaceutically acceptable salt thereof, wherein t is 0; and R^3 is phenyl optionally substituted with one to three R^{11} independently selected from the group consisting of fluoro, chloro, $-CF_3$, $-SF_5$, $-OCH_3$, $-OCF_3$, $-CF_2(CH_3)$ and $-OCHF_2$.

18. The compound according to claim 16, or a pharmaceutically acceptable salt thereof, wherein R^3 is thiophenyl optionally substituted with one to three R^{11} independently selected from the group consisting of fluoro, chloro, $-CF_3$, $-SF_5$, $-OCH_3$, $-OCF_3$, $-CF_2(CH_3)$ and $-OCHF_2$.

19. The compound according to claim 16, or a pharmaceutically acceptable salt thereof, wherein said compound is:

7-(4-methyl-1*H*-imidazol-1-yl)-2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[3,5-difluoro-4-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-(4-chloro-3,5-difluorophenyl)tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4,5-difluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-fluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione; or

2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-3-fluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione.

20. A compound 2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

21. A compound 2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-chloro-2-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

22. A compound 2-[(1*S*)-1-[(2*S*,5*R*)-5-(4-chloro-3,5-difluorophenyl)tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

23. A compound 2-[(1*S*)-1-[(2*S*,5*R*)-5-[3,5-difluoro-4-(trifluoromethyl)phenyl]tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

24. A compound 2-[(1*S*)-1-[(2*S*,5*R*)-5-[4-fluoro-2-(trifluoromethyl)phenyl]-tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

25. A compound 2-[(1*S*)-1-[(2*S*,5*R*)-5-[4,5-difluoro-2-(trifluoromethyl)phenyl]-tetrahydrofuran-2-yl]ethyl]-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.